KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Passes Above Fifty Day Moving Average – Time to Sell?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $22.99 and traded as high as $26.96. KalVista Pharmaceuticals shares last traded at $26.9450, with a volume of 6,431,370 shares.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KALV. Citizens Jmp cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $37.00 to $27.00 in a report on Friday, May 1st. Stifel Nicolaus raised their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.60.

KalVista Pharmaceuticals Stock Up 0.0%

The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The stock has a 50 day simple moving average of $22.99 and a 200 day simple moving average of $18.18. The firm has a market capitalization of $1.43 billion, a PE ratio of -7.79 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. As a group, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Nicole Sweeny sold 1,489 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the insider directly owned 59,291 shares in the company, valued at $1,587,812.98. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,489 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the sale, the chief financial officer directly owned 21,661 shares in the company, valued at $580,081.58. This trade represents a 6.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 261,295 shares of company stock valued at $4,764,294 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KALV. AQR Capital Management LLC bought a new stake in KalVista Pharmaceuticals in the first quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after acquiring an additional 2,939 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after acquiring an additional 12,263 shares in the last quarter. Creative Planning boosted its holdings in KalVista Pharmaceuticals by 20.0% in the second quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company’s stock worth $377,000 after acquiring an additional 5,573 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after acquiring an additional 1,458 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.